<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044339</url>
  </required_header>
  <id_info>
    <org_study_id>0177</org_study_id>
    <nct_id>NCT04044339</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Sponsor-open, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-5202 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists
      of 2 parts: Part A is a single ascending dose (SAD) study in healthy subjects and Part B is a
      multiple ascending dose (MAD) study in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Actual">November 27, 2019</completion_date>
  <primary_completion_date type="Actual">November 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of SAD of TD-5202 by assessing the number, severity and type of treatment emergent adverse events</measure>
    <time_frame>Day 1 through Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of MAD of TD-5202 by assessing the number, severity and type of treatment emergent adverse events</measure>
    <time_frame>Day 1 through Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of TD-5202 when given as an SAD: AUC</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of TD-5202 when given as a SAD: Cmax</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of TD-5202 when given as a SAD: Tmax</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Time to reach maximum observed concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an SAD: CL/F</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Oral Clearance (CL/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an SAD: Vz/F</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Terminal Phase Volume of Distribution(Vz/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an SAD: Kel</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Elimination Rate (Kel)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an SAD: t 1/2</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Halflife (t 1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: AUC</measure>
    <time_frame>Day 1 and Day 10</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: Cmax</measure>
    <time_frame>Day 1 and Day 10</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: Tmax</measure>
    <time_frame>Day 1 and Day 10</time_frame>
    <description>Time to reach maximum observed concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: C trough</measure>
    <time_frame>Day 2, 4, 6, 8</time_frame>
    <description>concentration at trough (after multiple dosing usually after reaching steady state) (C trough)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: Css</measure>
    <time_frame>Day 10</time_frame>
    <description>concentration at steady state (Css)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: CL/Fss</measure>
    <time_frame>Day 10</time_frame>
    <description>Oral clearance at steady state (CL/Fss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: Cmin</measure>
    <time_frame>Day 10</time_frame>
    <description>Concentration minimum (after single dosing) (Cmin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: Vz/Fss</measure>
    <time_frame>Day 10</time_frame>
    <description>Terminal phase volume of distribution at steady state (Vz/Fss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: Kel</measure>
    <time_frame>Day 10</time_frame>
    <description>Elimination Rate (Kel)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of TD-5202 when given as an MAD: t 1/2</measure>
    <time_frame>Day 10</time_frame>
    <description>Halflife (t 1/2)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TD-5202 for SAD (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive TD-5202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-5202 for MAD (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-5202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-5202</intervention_name>
    <description>Study Drug to be administered orally</description>
    <arm_group_label>TD-5202 for MAD (Part B)</arm_group_label>
    <arm_group_label>TD-5202 for SAD (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to be administered orally</description>
    <arm_group_label>Placebo for MAD (Part B)</arm_group_label>
    <arm_group_label>Placebo for SAD (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 19 - 55 years old

          -  Willing and able to give informed consent and comply with the study

          -  Medically healthy with no clinically significant medical history

          -  Body mass index (BMI) 18 to 32 kg/m2 and weighs at least 50 kg

          -  Women of child bearing potential must have a negative pregnancy test and use a highly
             efficient birth control method

          -  Males must use acceptable contraception

          -  Additional inclusion criteria apply

        Exclusion Criteria:

          -  Positive for hepatitis A, B or C, HIV or tuberculosis

          -  Clinically significant abnormalities of laboratory evaluations

          -  Have abnormal ECG or vital sign measurements

          -  Any acute illness at time of screening

          -  Have a current bacterial, parasitic, fungal or viral infection

          -  Uses or have used tobacco or nicotine-containing products within 6 months prior to
             screening

          -  Additional inclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TD-5202</keyword>
  <keyword>0177</keyword>
  <keyword>single ascending dose</keyword>
  <keyword>SAD</keyword>
  <keyword>multiple ascending dose</keyword>
  <keyword>MAD</keyword>
  <keyword>first-in-human</keyword>
  <keyword>Phase 1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

